Advances with polymer-free amphilimus-eluting stents

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• Percutaneous coronary intervention (PCI) outcomes are generally worse in diabetic patients compared to non-diabetics.
• Second-generation drug-eluting stents (DES) have improved outcomes, but disparities persist for diabetic individuals.
• The polymer-free Cre8 Amphilimus-eluting DES aims to reduce inflammatory responses and stent thrombosis.

Purpose of the Study:

• To evaluate the efficacy and safety of the Cre8 Amphilimus-eluting DES in patients with diabetes mellitus (DM).
• To compare the Cre8 DES performance in diabetic versus non-diabetic populations.
• To assess the Cre8 DES in real-world settings and specific subgroups of diabetic patients.

Main Methods:

• Clinical studies and real-world data collection (Investig8, Particip8).
• The RESERVOIR Clinical Trial specifically recruited patients with DM.
• Comparison of Cre8 DES against an everolimus-eluting DES (EES) in diabetic and overall populations.

Main Results:

• The Cre8 DES demonstrated equivalent efficacy and safety in both diabetic and non-diabetic patients in an initial clinical study.
• Real-world studies (Investig8) confirmed these findings.
• The RESERVOIR trial showed noninferiority to EES overall, with statistical superiority of Cre8 in diabetic patients with higher metabolic dysfunction.

Conclusions:

• The Cre8 Amphilimus-eluting DES is a valuable option for patients with diabetes mellitus undergoing PCI.
• Its polymer-free design may contribute to its favorable performance in diabetic populations.
• The stent shows promise in mitigating the adverse outcomes often seen in diabetic patients post-PCI.